scispace - formally typeset
M

Michikazu Abe

Researcher at University of Virginia

Publications -  6
Citations -  2733

Michikazu Abe is an academic researcher from University of Virginia. The author has contributed to research in topics: Circadian rhythm & Light effects on circadian rhythm. The author has an hindex of 4, co-authored 6 publications receiving 2564 citations. Previous affiliations of Michikazu Abe include Northwestern University.

Papers
More filters
Journal ArticleDOI

Resetting Central and Peripheral Circadian Oscillators in Transgenic Rats

TL;DR: It is hypothesize that a self-sustained circadian pacemaker in the SCN entrains circadian oscillators in the periphery to maintain adaptive phase control, which is temporarily lost following large, abrupt shifts in the environmental light cycle.
Journal ArticleDOI

Circadian rhythms in isolated brain regions.

TL;DR: The results indicate that the brain contains multiple, damped circadian oscillators outside the SCN, and the phasing of these oscillators to one another may play a critical role in coordinating brain activity and its adjustment to changes in the light cycle.
Journal ArticleDOI

Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons.

TL;DR: Results indicate that lithium acts directly on the mammalian suprachiasmatic nucleus (SCN) to lengthen the free-running period of individual neurons.
Journal ArticleDOI

Photic and circadian expression of luciferase in mPeriod1-luc transgenic mice in vivo

TL;DR: This approach demonstrates that the 6.75-kb mPer1 promoter fragment is sufficient to confer both circadian and photic regulation in vivo and reveals a potential posttranscriptional regulatory mechanism within the mammalian circadian oscillator.
Patent

Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression

TL;DR: In this paper, an isolated Period 1 (Per1) promoter DNA inducing rhythmical expression of a gene operably linked to the promoter DNA was presented, which is useful in the screening of pharmaceutical drugs against diseases and disorders pertaining to the circadian rhythm.